Novocure

Novocure ROA

The Return on Assets (ROA) of Novocure (NVCR) as of Nov 4, 2026 is -16.94 %. In the previous year, Return on Assets (ROA) was -13.59 % — a change of 24.62% (lower).

ROA

-16.94 %

YoY

24.62%

Last updated:

In 2025, Novocure's return on assets (ROA) was -16.94 %, a 24.62% increase from the -13.59 % ROA in the previous year.

The Novocure ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-18.71 USD
Jan 1, 2019
-1.51 USD
Jan 1, 2020
1.88 USD
Jan 1, 2021
-5.12 USD
Jan 1, 2022
-7.77 USD
Jan 1, 2023
-18.06 USD
Jan 1, 2024
-13.59 USD
Jan 1, 2025
-16.94 USD
The Novocure ROA history
YEARROAYoY
-16.94 %+24.62%
-13.59 %-24.77%
-18.06 %+132.63%
-7.77 %+51.64%
-5.12 %-371.96%
1.88 %-224.86%
-1.51 %-91.94%
-18.71 %-19.52%
-23.24 %-50.27%
-46.74 %+28.74%
-36.31 %-46.96%
-68.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novocure Stock analysis

What does Novocure do? Novocure Ltd. is a global scientific-based company that was founded in Israel in 2000. Its focus was originally on researching and developing tumor therapies. Since then, Novocure has become one of the leading companies in cancer research and treatment, specializing in the development of innovative cancer therapies. The business model of Novocure is based on developing powerful and innovative treatment methods for a variety of cancer types, including brain, pancreatic, prostate, and lung cancer. The company is committed to developing new cancer treatments that improve the lives of patients and meet their needs. Novocure also offers a wide range of products, including several treatment options based on the use of electric fields. These electric fields can specifically target the tumor and inhibit cell division without damaging the surrounding healthy tissue. This innovative technology is also called "tumor therapeutic fields" (TTF). TTF is a non-invasive procedure that is able to destroy cancer cells and inhibit the growth of cancer cells using targeted radio waves. The company also has its own research and development department dedicated to the development of innovative cancer therapies. In collaboration with numerous leading medical experts and researchers worldwide, Novocure advances cancer treatment research and development, striving to improve the treatment of cancer patients worldwide. Novocure operates three main divisions: Onco-Support, Onco-Centers, and Medical Research. The Onco-Support division offers specialized services to patients, such as training on the use of TTF devices, assistance with insurance issues, facilitating access to TTF devices, and help with setting up TTF devices. The Onco-Centers division operates various clinics specialized in the treatment of skin and brain cancer. Here, patients can benefit from the use of TTF devices and receive this therapy from experienced specialists. The Onco-Centers also provide tailored support and counseling for the needs of patients. The Medical Research division of the company also conducts research and development activities in the field of cancer therapies. Here, new therapies and procedures for cancer treatment are explored and developed, with a particular focus on the application of TTF devices. The goal of this research is to develop innovative cancer treatments that improve the lives of cancer patients and give them hope for a better future. Overall, Novocure Ltd. is an innovative and customer-oriented company dedicated to the treatment of cancer patients. The company invests heavily in research and development to develop innovative therapies and products that meet the high needs of cancer patients. The use of TTF technology is a significant step in cancer treatment, and Novocure Ltd. is leading the global development in this regard. Novocure is one of the most popular companies on Eulerpool.

ROA Details

Understanding Novocure's Return on Assets (ROA)

Novocure's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Novocure's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Novocure's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Novocure’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Novocure stock

Return on Assets (ROA) of Novocure is -16.94 % in 2025.

Return on Assets (ROA) of Novocure changed from -13.59 % to -16.94 %, representing a 24.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Novocure since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Novocure with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Novocure

All Key Metrics — Novocure